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clinical (bedside) and laboratory (bench). The clinician
always wants to know what the fungus is and how to
treatment the mycosis. Fungal pathogens are often stealthy
and difﬁcult to detect in infected patients during the early
stages of the diseases and this is when therapies would be
the most effective. Routine techniques commonly employed
in the detection of fungal diseases including microscopic
examination, culturing and serology are seriously hampered
by lengthy waits of times for results and low accuracy. The
clinician may want prophylaxis or to use empirical antifungal
treatment to see if it does/does not work. The problem is
that some of the patients do not respond to the antifungal
treatment, because the doctor lacked sufﬁcient evidence of
fungus infection to give the doctor conﬁdence to continue
treatment. Accurate and early diagnosis of fungal diseases
is critical for managing mycotic diseases. Our experience is
before starting antifungal treatment, we need to be sure
the tissue was invaded by a fungus. This is usually done by
direct microscopic examination (DME) of KOH preparations.
Good specimens are the key point that directly affects
the quality of microscopic evidence and culture. The most
important aspect is culturing samples on different media
with or without chloramphenicol and cycloheximide and
incubated at room temperature and 37ºC. PCR-based no-
culture methods are necessary in the cases of culture
negative, morphologic identiﬁcation not success, and, to
prove the species identiﬁed by routine. Early treatment
could save a patient’s life. We start treatment at the time
we have the proof of fungal infection, i.e., KOH positive.
Itraconazole, ﬂuconazole, terbinaﬁne, amphotericin B or its
liposome form, can be used alone or in combination based
on the fungal species involved and the site of infection.
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Scheme for diagnosis and treatment of invasive fungal infections.
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M. Omata*. Yamanashi Central Hospital and University of
Tokyo, Japan
The diagnosis and treatment of HCV (Hepatitis C Virus) has
been changing drastically for the last 20 years. Therefore,
we feel the need to revise the guidelines maybe every 2 to
3 years to update the knowledge for clinical use.
The last publication on HCV guideline was 1992 by Dr. Geoff
McCaugh and and myself with 17 co-authors. However after
that, there is remarkable progress in understanding of the
pathogenesis and natural courses of HCV infection. For
example, the discovery of IL28b SNP revolutionized and
changed interferon treatment indications.
Recently, the SNP analysis chronicle HCV infection was
performed on large scale matters in Japanese patients,
and it was revealed several signiﬁcant SNPs were identiﬁed
to inﬂuence on the natural courses of the hepatitis virus
infection. Furthermore, the remarkable effort to develop
the innovative drugs for the treatment and cure of HCV
infection has been conducted for the last 10 years, and new
Protease Inhibitors will be on the market shortly. These new
drugs may change the paradigm of the treatment of HCV
infections totally, and we are now in vision even the total
cure of the diseases. Therefore, we are now in process to
revise APASL guidelines to be able to catch up the incredible
progress of the management on HCV infections.
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Personalized therapy based on current standard of care,
pegylated interferon-a (PegIFN) plus ribavirin (RBV), has
become the mainstay for treatment of chronic hepatitis C
virus (HCV).
Genotype-guided therapy, based on HCV genotype,
recommended a 48-week regimen of PegIFN plus weight-
based RBV (1000 1200mg/d) for HCV genotype 1 or 4
(HCV-1/4); and a 24-week regimen of PegIFN plus ﬁxed,
low dose of RBV (800 mg/d) for HCV-2/3 infection.
The sustained virological response (SVR, serum HCV RNA
<50 IU/ml throughout 6 months of post-treatment follow-up
period) rate is around 50% and 83% for HCV-1/4 patients and
HCV-2/3 patients, respectively in Caucasian; and 70 75% and
85 90% in Asian patients, respectively. The optimal regimens
for HCV-5 or 6 remain to be determined.
Recently, response-guided therapy, based on on-treatment
virological responses, has become the new era of care. A
shorter 24-week regimen for HCV-1 with lower baseline viral
loads and a rapid virological response (RVR, serum HCV RNA
<50 IU/ml at 4 weeks of treatment) and an abbreviated 16-
week regimen with weight-based, standard dose of RBV for
HCV-2/3 could provide equal efﬁcacy to genotype-guided
SOC. By contrast, treatment should be stopped for HCV-1
patients without an early virological response (EVR, serum
HCV RNA <50 IU/ml or a 2 logs decline of HCV RNA from
baseline after 12 weeks of therapy). Furthermore, EVR has
been suggested to be subdivided into RVR, complete EVR
(no RVR, but HCV RNA <50 IU/ml at week 12) and partial
EVR (HCV RNA >2 log drop in HCV RNA but still detectable at
week 12) to further improve the prediction of patients who
are likely to achieve an SVR and may allow for extending
treatment duration to 72 weeks, especially for those of slow
responders.
More recently, the development of direct antiviral agents
(DAA, formally named speciﬁcally targeted antiviral therapy
for HCV, STAT-C) is ongoing. DAA has increased the number
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of therapeutic options for CHC patients. Some of them
have shown promising results in clinical trials. A number
of HCV polymerase inhibitors are in phase I or II trials
and entry inhibitors are under development. Two HCV
NS3 4A protease inhibitors (PIs) have completed phase
III studies. Data from phase 2 studies have shown that
a substantial number of HCV-1 patients could achieve an
SVR with DAA plus Peg-IFN/RBV for even 12 or 24 weeks.
Phase III studies of Boceprevir or Telaprevir demonstrated
PI/Peg-IFN/RBV (with or without “lead in” pretreatment)
based on strategy of week 4 response-guided therapy
could dramatically improve the SVR rates to 63 75% in
HCV-1 treatment-naive patients. In addition, the boceprevir
regimens consistently achieved SVR rates of approximately
40% to 50% among the more difﬁcult-to-treat patients, such
as blacks and previous nonresponders. However, subgroup
analysis demonstrated that the beneﬁts of adding boceprevir
was only observed among patients carrying unfavorable IL28
genotype. Therefore, excitement over these impressive
results needs to be tempered by the complexity of the
regimens, the high rates of anemia, and the development of
boceprevir resistance-associated variants, especially among
treatment-experienced patients.
CS4.2 Directly acting antivirals against HCV
X.G. Dou*. Department of Infectious Disease, Shengjing
Hospital afﬁliated to China Medical University, Shenyang,
China
Abstract not available
CS4.3 Ursodeoxycholic acid treatment for HCV
patients
S.U. Kim*. Department of Internal Medicine, Yonsei
University College of Medicine, Seoul, Korea
Abstract not available
CS4.4 Prepare for the new therapies: Current status
and policy in China
L. Wei *. Peking University People’s Hospital, Beijing,
China
Abstract not available
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CS5.2 Antimicrobial resistance in China
Y.H. Xiao*. Laboratory of Diagnosis and Treatment of
Infectious Diseases, 1st afﬁliated Hospital, School of
Medicine, Zhejiang University, Hangzhou, China
Antimicrobial resistance is getting a challenge and threat to
public healthcare, which was announced as one of the most
severe public healthcare crisis by WHO. Strategies for the
containment of AMR include resistant surveillance, resistant
mechanism study, prudent application of antimicrobial
agents and new antibiotic development, etc. It is very
important to clinicians to prescribe antibiotics referring
to the bacterial resistant monitoring results, and resistant
mechanism researches would elucidate the biological basis
of antibiotic resistance and provide basic information for
overcoming AMR and ﬁnding new antibiotic target. The
national and local bacterial resistant surveillance networks
have been set up and the researches on the resistant
mechanisms have achieved much valuable results.
1. Antibiotic resistant surveillance networks in China:
Companying with the social-economic development, health-
care improvement, lifespan elongation and communicable
disease decrement, infections, especially nosocomial
infections and infections with resistant germs are emerging
as one of the major morbidity and mortality in
China. Bacterial resistance has got also an unavoidable
public health problem. It is becoming a consensus of
clinician, microbiologist, pharmacist, healthcare ofﬁcials
and pharmaceutical companies to investigate bacterial
resistance, study resistant mechanisms and ﬁnd out
effective handling measures. Ofﬁcial facilities, medical
institutions and pharmaceutical companies conducted most
of the bacterial resistant surveillance.
Ofﬁcial bacterial resistance surveillance: The national and
provincial antimicrobial resistant surveillance networks
were established after 2005, the national network is named
Mohnarin (MOH national antibacterial resistant investigation
net ) because of the initiation of MOH in 2005, the
major mission of Mohnarin is to get national bacterial
resistant information and assist the antimicrobial agent
administration in China. This network was composed of some
150 tertiary hospitals across the country. All the hospitals
conduct surveillance by a common protocol, but each
hospital do not need to modify its own routine daily clinical
microbiological schedule, such as bacterial identiﬁcation,
antibiotic sensitive panel. The investigational results are
submitted to Mohnarin Center for data analysis. WHONET
software is employed for data processing. For promotion
the surveillance quality, there are some training course
and workshop focusing on the QC/QA and Whonet software
use. Mohnarin should generate yearly report to MOH. By
the regulation of MOH, some provinces have their own
AMR surveillance network, which consist of both tertiary
hospitals and primary hospitals. Mohnarin is not only the
largest network and but also the high quality one.
Medical institution bacterial resistance surveillance: Most
of tertiary hospitals in China have their regular or irregular
bacterial resistant surveillance carried out by their clinical
microbiology units or nosocomial monitoring facilities.
Pharmaceutical company bacterial resistant surveillance:
For the purpose of getting bacterial resistance to some
special antibacterial agent, some pharmaceutical company
occasionally organized bacterial resistant surveillance.
Although with participation of scientiﬁc members, the
business aim makes the clinical value of the results is
limited.
2. Prevalence of bacterial resistance: By the results
of Mohnarin 2008, 160513 bacterial isolates and their
antibacterial susceptibility data were collected during the
survey period in 89 tertiary hospitals, which included
50856 (31.68%) Gram-positive and 106957(68.32%) Gram-
negative bacterial strains. Staphylococcus (32378 strains),
enterococcus (12127 strains) and streptococcus (5138
strains) were the top three gram-positive isolates, while
Escherichia coli (26957 strains), Pseudomonas aeruginosa
(18347 strains) and Klebsiella pneumoniae (16396 strains)
were the most common Gram-negative isolates. Methicillin-
resistant Staphylococcus aureus (MRSA) and Staphylococcus
epidermidis were 67.6% and 83.2%, respectively; 3.8%
of Streptococcus pneumoniae was penicillin resistant.
Glycopeptides resistant enterococcus was rare. More than
40% of E. coli and other enterobacteria were resistant to
